EFTA01450729.pdf

William Blair & Company, LLC. Exhibit 1 ARIAD Pharmaceuticals, Inc. Sum-of-Parts Fair Value (dollars in thousands) Stage of Estimated Probability of Percentage of Probability. Value Percentage of Drug Peak Sales Development Launch Date Commercialization Sales to Company Adjusted NPV per Share Fair Value Iclusig-CML January 2013/ 9746.822 Marketed 100% 100% $1,843,975 $9.85 83.4% Worldwide July 2013 AP28113—ALK* NSCLC S280918 Phase IflI 1-122016 81% 100% $325,268 $1.74 14.7% Worldwide Subtotal $2,189,243 $11.59 98.2% Net Cash at Yearend 2014 $63,406 $0.34 2.9% Net Present Value of additional Gain (Loss)' ($22,727) ($0.12) (1.0%) Sum-of-Parts Fair Value $2,209,922 $11.81 100.0% - Includes costs nal *Golly reined to programs above Sources. Company reports and %ma'am Emir 8 Company. L L.C. estimates 5 I Y. Katherine Xu, Ph.D. CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0106554 CONFIDENTIAL SDNY_GM_00252738 EFTA01450729